CN113350390A - Total sesquiterpene lactone of saussurea involucrata, preparation method and pharmaceutical application thereof - Google Patents
Total sesquiterpene lactone of saussurea involucrata, preparation method and pharmaceutical application thereof Download PDFInfo
- Publication number
- CN113350390A CN113350390A CN202110629111.9A CN202110629111A CN113350390A CN 113350390 A CN113350390 A CN 113350390A CN 202110629111 A CN202110629111 A CN 202110629111A CN 113350390 A CN113350390 A CN 113350390A
- Authority
- CN
- China
- Prior art keywords
- sesquiterpene lactone
- total sesquiterpene
- saussurea
- total
- hexane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229930009674 sesquiterpene lactone Natural products 0.000 title claims abstract description 68
- 150000002107 sesquiterpene lactone derivatives Chemical class 0.000 title claims abstract description 68
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 title claims abstract description 63
- 241001145025 Saussurea involucrata Species 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000000284 extract Substances 0.000 claims abstract description 32
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 30
- 241000133134 Saussurea Species 0.000 claims abstract description 30
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000003814 drug Substances 0.000 claims abstract description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000003208 petroleum Substances 0.000 claims abstract description 14
- 241000196324 Embryophyta Species 0.000 claims abstract description 13
- 239000011347 resin Substances 0.000 claims abstract description 13
- 229920005989 resin Polymers 0.000 claims abstract description 13
- 239000000287 crude extract Substances 0.000 claims abstract description 10
- 239000012046 mixed solvent Substances 0.000 claims abstract description 10
- 238000010898 silica gel chromatography Methods 0.000 claims abstract description 7
- 230000002926 anti-osteoarthritic effect Effects 0.000 claims abstract description 5
- 239000003463 adsorbent Substances 0.000 claims abstract description 4
- 238000010298 pulverizing process Methods 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 238000010828 elution Methods 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 7
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 claims description 6
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims description 5
- 238000001179 sorption measurement Methods 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 238000004458 analytical method Methods 0.000 claims description 4
- 238000005516 engineering process Methods 0.000 claims description 4
- 239000000741 silica gel Substances 0.000 claims description 4
- 229910002027 silica gel Inorganic materials 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 3
- 210000001612 chondrocyte Anatomy 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 8
- 230000001575 pathological effect Effects 0.000 abstract description 8
- 230000006378 damage Effects 0.000 abstract description 7
- 206010061218 Inflammation Diseases 0.000 abstract description 6
- 230000004054 inflammatory process Effects 0.000 abstract description 6
- 230000035755 proliferation Effects 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 210000001188 articular cartilage Anatomy 0.000 abstract description 3
- 208000014674 injury Diseases 0.000 abstract description 3
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 abstract description 2
- 206010057178 Osteoarthropathies Diseases 0.000 abstract description 2
- 208000027418 Wounds and injury Diseases 0.000 abstract description 2
- 230000006907 apoptotic process Effects 0.000 abstract description 2
- 235000013305 food Nutrition 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 20
- KHSCYOFDKADJDJ-NQLMQOPMSA-N Cynaropicrin Chemical compound OCC(=C)C(=O)O[C@H]1CC(=C)[C@@H]2C[C@H](O)C(=C)[C@@H]2[C@H]2OC(=O)C(=C)[C@H]12 KHSCYOFDKADJDJ-NQLMQOPMSA-N 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 201000008482 osteoarthritis Diseases 0.000 description 8
- 206010003246 arthritis Diseases 0.000 description 7
- -1 phenylpropanoid glycoside Chemical class 0.000 description 7
- 239000007788 liquid Substances 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- STQKFHDZSADKCG-UHFFFAOYSA-N cynaropicrin Natural products OC1CC2C(C3OC(=O)C(=C)C3C(CC2=C)OC(=O)C(=C)O)C1=C STQKFHDZSADKCG-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000005222 synovial tissue Anatomy 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 208000009386 Experimental Arthritis Diseases 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- 206010023232 Joint swelling Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000760744 Saussurea americana Species 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 208000018937 joint inflammation Diseases 0.000 description 3
- 239000002398 materia medica Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 210000001258 synovial membrane Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 241001522110 Aegilops tauschii Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 235000007516 Chrysanthemum Nutrition 0.000 description 2
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102000013691 Interleukin-17 Human genes 0.000 description 2
- 108050003558 Interleukin-17 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 2
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 102000014128 RANK Ligand Human genes 0.000 description 2
- 108010025832 RANK Ligand Proteins 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 229930013686 lignan Natural products 0.000 description 2
- 150000005692 lignans Chemical class 0.000 description 2
- 235000009408 lignans Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229940023488 pill Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229930004725 sesquiterpene Natural products 0.000 description 2
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000002437 synoviocyte Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 244000026873 Alternanthera philoxeroides Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 206010005963 Bone formation increased Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 241001149724 Cololabis adocetus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 1
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000977585 Saussurea medusa Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000329 aluminium sulfate Inorganic materials 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 235000011128 aluminium sulphate Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 210000001264 anterior cruciate ligament Anatomy 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940092738 beeswax Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 229930015704 phenylpropanoid Natural products 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 210000001226 toe joint Anatomy 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07G—COMPOUNDS OF UNKNOWN CONSTITUTION
- C07G5/00—Alkaloids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Polymers & Plastics (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a total sesquiterpene lactone of saussurea involucrate, a preparation method and a medicinal application thereof, belonging to the field of preparation of effective components of traditional Chinese medicines and natural medicinal chemistry. Pulverizing dried whole plant of saussurea involucrata, extracting with n-hexane or petroleum ether and ethyl acetate mixed solvent to obtain crude extract, and enriching by macroporous adsorbent resin or silica gel column chromatography to obtain total sesquiterpene lactone extract of saussurea involucrata. The extract has the pharmacological effects of remarkably reducing inflammatory reaction of osteoarthropathy animals, inhibiting chondrocyte apoptosis, promoting chondrocyte proliferation and remarkably reducing pathological injury of articular cartilage, and can be used for preparing various medicaments or health-care foods with anti-osteoarthritis effect.
Description
Technical Field
The invention relates to the field of preparation of effective components of traditional Chinese medicines and natural medicinal chemistry, in particular to a total sesquiterpene lactone of saussurea involucrate, a preparation method and medical application thereof.
Background
The feverfew (Compositae) Saussurea (Saussurea) plants are mainly distributed in Asia and Europe, contain abundant sesquiterpenes, triterpenes, flavones, lignans and other chemical components, have obvious pharmacological activities of tumor resistance, inflammation resistance, aging resistance and the like, and are widely and long-term applied in folks.
Saussurea involucrata (Fisch.) of saussurea is a perennial herb of saussurea, and is originally recorded in the atlas of Chinese higher plants. The Chinese materia medica and the Xinhua materia medica gang principle record that the taste is pungent and bitter; the cold nature, the whole herb is used as the medicine, has the efficacies of dispelling wind and clearing heat, and removing dampness and relieving pain, is used for treating rheumatoid arthritis, damp-heat diarrhea and other symptoms, and has high medicinal value. The Tibetan medicine can be used for promoting vomiting, relieving fever and pain, and can be used for treating chronic rheumatic arthritis. The Chinese plant record that it is distributed in Beijing, Heilongjiang, Jilin, Liaoning, Hebei, Shanxi, inner Mongolia and other places, and has distribution in Korea, Japan, Mongolia and Russia, and originates from grassland, forest edge, bush, valley meadow and other places with elevation of 300 + 2200 meters. In addition, the American Mao Ju is also recorded in the monographs of Chinese medicine, the dictionary of famous Chinese medicine, the dictionary of prescriptions for analgesic in the past, the compendium of modern materia Medica, the plant medical record of Chinese medicine, the plant medical record of Changbai mountain, the plant resource record of Chinese Daxing anling Mongolia and the plant record of Heilongjiang province. Has abundant morphological research and folk application at home and abroad. In Korea, saussurea involucrata is widely used for treating diseases such as hypertension, hepatitis and arthritis, and in Russia, folk, diarrhea is treated with herbal decoction. Although widely distributed in China, the saussurea involucrate (traditional Tibetan medicine in China) which is a congeneric plant is not fully developed and utilized as a medicinal plant resource.
In recent years, the chemical composition of saussurea americana has been increasingly studied, and among them, many of korea and russian scholars have studied the chemical composition of saussurea americana, and 59 chemical compositions such as monoterpene, sesquiterpene and sesquiterpene lactone, flavone, lignan, phenylpropanoid glycoside, etc. have been identified from saussurea americana. Wherein the sesquiterpene lactone component is a characteristic component of saussurea involucrate.
Osteoarthritis (OA) is a joint degenerative disease related to multiple factors such as inheritance, trauma, metabolism, stress change, inflammation and the like, is well developed in middle-aged and elderly people, takes articular cartilage degeneration and hyperosteogeny as pathological features, is clinically manifested as joint pain, swelling, stiffness, limited movement and the like, and can finally cause joint dysfunction and disability. With the aging population and the increasing prevalence of obesity, hip and knee joint OA is the 11 th leading cause of disability worldwide, creating a heavy economic and social burden. At present, the treatment of OA is limited to symptomatic treatment, and drugs for delaying disease progression are not available, and the pathological mechanism, the treatment target and the drugs need to be researched urgently.
Until now, no relevant research report of applying sesquiterpene lactone components of saussurea camomila to preventing and treating osteoarthritis is available at home and abroad.
Disclosure of Invention
The invention provides a total sesquiterpene lactone of aeolian chrysanthemum, a preparation method and a medicinal application thereof.
The technical scheme adopted by the invention is that the method is obtained by the following steps:
pulverizing dried whole plant of saussurea involucrata, extracting with n-hexane or petroleum ether and ethyl acetate mixed solvent to obtain crude extract, and enriching by macroporous adsorbent resin or silica gel column chromatography to obtain total sesquiterpene lactone extract of saussurea involucrata.
The enrichment by macroporous adsorption resin refers to that the crude extract is added into a macroporous resin column D4020, D101 or AB-8, gradient elution is carried out by using an ethanol-water mixed solvent, liquid chromatography-mass spectrometry (LC-MS) technology is adopted for analysis and detection, fractions containing sesquiterpene lactone are collected, and the fractions are combined and dried to obtain the total sesquiterpene lactone.
The gradient elution of the ethanol-water mixed solution is carried out by sequentially adopting 10-30% and 40-90% of ethanol in percentage by mass.
The silica gel column chromatography of the invention refers to that the crude extract is added into a silica gel column, gradient elution is carried out by using mixed organic solvent, fractions containing sesquiterpene lactone are collected, and the total sesquiterpene lactone is obtained after merging and drying.
The mixed organic solvent is n-hexane: ethyl acetate is 20: 1-1: 20; n-hexane: dichloroethane is 30: 1-1: 30; petroleum ether-: ethyl acetate is 15: 1-1: 20; petroleum ether: dichloroethane is 30: 1-1: 30; n-hexane: acetone is 20:1 to 1: 20.
The total sesquiterpene lactone in the saussurea involucrate total sesquiterpene lactone is not less than 50% by mass.
The invention relates to application of total sesquiterpene lactone of saussurea involucrata in preparation of anti-osteoarthritis medicines.
When the invention is used for preparing the anti-osteoarthritis medicine, the oral or non-oral administration of the medicine is safe. In case of oral administration, it may be administered in any conventional form, such as powder, granule, tablet, capsule, pill, drop pill, soft capsule, floating agent, oral liquid, suspension, syrup, buccal tablet, spray or aerosol, etc. when the drug is not administered orally, any conventional form may be employed, such as suppository, injection intravenous injection, intramuscular injection, ointment, inhalant, etc.
The present invention is made up by using solid or liquid excipient, the solid or liquid excipient used in this invention is well known in the art, and the excipient of solid preparation is lactose, starch, dextrin, calcium carbonate, synthetic or natural aluminium sulfate, magnesium chloride, magnesium stearate, sodium bicarbonate, dried yeast and other liquid preparation, and the excipient of ointment such as water, glycerin, propylene glycol, simple syrup, ethanol, ethylene glycol, polyethylene glycol, sorbitol and other ointment can use fat oil, aqueous lanolin, vaseline, glycerin, beeswax, wood wax, liquid paraffin, resin, higher wax and other hydrophobic or hydrophilic agent.
The invention has the advantages that the total sesquiterpene lactone with the anti-inflammatory effect is extracted and enriched from the saussurea involucrate for the first time, the extract is rich in cynaropicrin, saussurea involucrate alkali and other components, the preparation process of the extract is simple, the extract is suitable for industrial production, the extract has the pharmacological effects of obviously reducing the inflammatory reaction of osteoarthropathy animals, inhibiting the apoptosis of chondrocytes, promoting the proliferation of the chondrocytes and obviously reducing the pathological damage of articular cartilage, and can be used for preparing various medicaments or health-care foods with the anti-osteoarthritis effect.
Detailed Description
Example 1
Taking 1.0kg of dry whole herb of saussurea involucrata, crushing, sieving by a 40-mesh sieve, carrying out reflux extraction by adopting a mixed solvent of n-hexane and petroleum ether (10: 3), carrying out reflux time for 3 hours each time, carrying out reflux times for 3 times, merging extracting solutions, concentrating under reduced pressure, drying, adding 200mL of water for dissolving, adding the obtained solution to AB-8 macroporous adsorption resin, washing the obtained solution until the obtained solution is colorless, eluting the obtained solution by 30% of ethanol, collecting 30% ethanol eluent, concentrating under reduced pressure, and drying to obtain 18.9g of the total sesquiterpene lactone extract of the saussurea involucrata.
Example 2
Taking 1.0kg of dry whole herb of saussurea involucrata, crushing, sieving by a 40-mesh sieve, carrying out reflux extraction by adopting a mixed solvent of n-hexane and petroleum ether (2: 1), carrying out reflux time of 3 hours each time, carrying out reflux times of 3 times, merging extracting solutions, concentrating under reduced pressure, drying, adding 250mL of water for dissolving, adding D4020 macroporous adsorption resin, washing until the solution is colorless, eluting by 50% ethanol, collecting 50% ethanol eluent, concentrating under reduced pressure, and drying to obtain 23.5g of the total sesquiterpene lactone extract of the saussurea involucrata.
Example 3
Taking 1.0kg of dry whole herb of saussurea involucrata, crushing, sieving with a 40-mesh sieve, performing reflux extraction by using a petroleum ether-ethyl acetate (5: 1) mixed solvent, performing reflux for 3 hours each time, performing reflux times for 3 times, merging extracting solutions, performing reduced pressure concentration, drying, adding into a silica gel column (200 meshes and 300 meshes), eluting by using petroleum ether-ethyl acetate (15: 1-1: 20), performing LC-MS detection, collecting an eluent containing sesquiterpene lactone, performing reduced pressure concentration, and drying to obtain 26.8g of the total sesquiterpene lactone extract of the saussurea involucrata.
The invention is further illustrated below by means of experimental examples.
Experimental example 1 identification of Components contained in Total sesquiterpene lactone of saussurea involucrate
Cynaropicrin (cynaropicrin), colorless oil. HR-MS showed M/z 347[ M + H]+The quasi-molecular ion peak can be analyzed by combining with NMR spectrum to obtain the molecular formula C19H22O6。
1H NMR(600MHz，CD3OD) spectrum gives a total of 19 proton signals, including δ: 6.33(1H, d, J ═ 1.2Hz, H-3 '), 6.15(1H, d, J ═ 3.5Hz, H-13),5.99(1H, d, J ═ 1.5Hz, H-3 '), 5.67(1H, d, J ═ 3.1Hz, H-13),5.46(1H, s, H-15),5.37(1H, s, H-15),5.18(1H, s, H-14),5.17(1H, ddd, J ═ 15.1,12.6,7.8Hz, H-8),4.94(1H, s, H-14),4.56(1H, t, J ═ 7.1Hz, H-3),4.33(1H, s, H-4 '), 4.27(1H, ddd, 10, J-14), 4.56(1H, t, J ═ 7.1Hz, H-3 dt), 4.33(1H, H-4.27 (1H, ddh, 10, J ═ 8, 7.9, H-3, 1H-0, 1H-3, ddh-3 Hz, 1H-3, ddh-3, J-3, 1H-3, 1,3, 1H-3, 1H-7.9, 3, 1H, 3, 1,3, 1H-3, 1H-7, 1H-3, 1H-13, 1H-3, 1H, 3, H-3, 1,3, 1H, H-13, H, 1H, 1,3, 1, H-3, 1H, 1, H, 1, J-13, H, J-7, H, 1, H, 1H, 1, J-7, 1, H, J-7, 1H, 1, H, 1, H, 1H-7, H, 1, J-13, 1, H, J-7, 1H-3, J-7, 1, J-7, H, 1, H, 1H, J-7, 1H-7, J-7, t, J ═ 9Hz, H-5),2.76(1H, dd, J ═ 14.6,5.1Hz, H-9),2.43(1H, dd, J ═ 14.6,3.5Hz, H-9),2.12(1H, ddd, J ═ 12.6,7.1,3.5Hz, H-2),1.77(1H, ddd, J ═ 12.6,7.1,3.5Hz, H-2).
13C NMR(600MHz，CD3OD) spectrum gives 19 carbon signals including δ: 46.01(C-1),39.83(C-2),73.97(C-3),153.87(C-4),51.87(C-5),75.46(C-6),46.01(C-7),80.12(C-8),37.45(C-9),141.77(C-10),139.57(C-11),166.37(C-12),122.16(C-13),117.95(C-14),113.23(C-15),154.48(C-1’),143.88(C-2’),125.77(C-3’),61.45(C-4’)。
experimental example 2 LC-MS assay of Total sesquiterpene lactones of saussurea medusa
Taking the total sesquiterpene lactone extract of saussurea involucrate, obtained in example 3, and identifying or preliminarily identifying the total sesquiterpene lactone extract of the saussurea involucrate by comparing with a reference substance or analyzing retention time, accurate molecular weight and typical fragments by combining an ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UPLC-Q/TOF-MS) technology with a UNIFI natural product analysis platform, wherein 15 chemical components are identified in total and are respectively 8 alpha-O- (2, 3' -dihydroxyisobutyryl) -11 beta, 13-dihydrodeacylated cynaropicrin; 8 α -O- (3 '-hydroxy-3' -methylbutyryl) deacylated cynaropicrin; camomile base A; camomile base B; camomiline C; camomiline D; camomiline E; camomiline F; camomiline G; 11 β, 13-dihydrodeacylated cynaropicrin; a saury toxin; cynaropicrin; deacylated cynaropicrin; 11 β, 13-dihydrodeacylated cynaropicrin 8-O- β -D-glucoside; 8 alpha- (4' -hydroxyl seneciloyloxy) dehydromefenacin C.
Experimental example 3 inflammation inhibitory Effect of Total sesquiterpene lactone of saussurea involucrata on rat osteoarthritis model
The method comprises the following steps: in vitro, an articular chondrocyte damage model is established by adopting LPS induction, and the intervention is carried out by using the total sesquiterpene lactone extracts of the saussurea involucrate with different concentrations. The proliferation and morphology of chondrocytes were examined by staining, and the levels of inflammatory factors such as iNOS, TNF-. alpha., IL-6 and IL-1. beta. were examined by ELISA.
In vivo study, rat anterior cruciate ligament is surgically detached to establish an osteoarthritis model, and Alternanthera philoxeroides total sesquiterpene lactone extract is injected into the joint cavity every other day, and the pathological injury condition is detected by continuous administration for 30 days and by HE and safranine fast green staining.
As a result: the saussurea involucrate total sesquiterpene lactone extract can obviously promote the proliferation of chondrocytes, and the proliferation effect is most obvious at the concentration of 100 mu mol/L (p is less than 0.01); compared with the model group, the activity of the chondrocytes is obviously increased (p is less than 0.05), and the levels of inflammatory factors such as IL-1 beta, IL-6, TNF-alpha, iNOS and the like are obviously reduced (p is less than 0.01); pathological examination results show that compared with a model group, the pathological damage degree of joint softness of the saussurea involucrate total sesquiterpene lactone extract group is obviously reduced.
And (4) conclusion: the total sesquiterpene lactone extract of saussurea involucrata can inhibit the expression and release of inflammatory factors caused by LPS, relieve the degradation of cartilage extracellular matrix and relieve the progress of osteoarthritis.
Experimental example 4 Effect of Total sesquiterpene lactones of saussurea involucrata on collagen-induced arthritis model rats
The method comprises the following steps: female rats were randomly divided into normal group, model group, positive control group, and high, medium, and low dose groups of total sesquiterpene lactone extract of saussurea involucrate, each group containing 12 rats. Except for the normal control group, the other groups all construct a CIA model: bovine type II collagen was dissolved in 0.1mol/L acetic acid to prepare a 2mg/mL collagen solution. The next day was thoroughly emulsified with an equal volume of Freund's complete adjuvant (CFA) in an ice bath to prepare a collagen emulsion at a concentration of 1 mg/mL. Outside a normal group, the other groups of rats are injected with 0.4mL of collagen emulsion at multiple points in the skin, 0.2mL of collagen emulsion is administered in the same way after 1 week, a CIA rat model is copied, gavage is started on the 7 th day, 3 doses of aeolian chrysanthemum total sesquiterpene lactone extract are administered, the administration lasts for 4 weeks, blood is taken from veins after the administration is finished, joint synovium is separated after the rats are killed, and the ELISA method is adopted to detect the content of IL-12, HIF-1 alpha and IL-10 in the serum.
Joint inflammation index score: the degree of joint involvement of rats was evaluated according to the 5-point scale. The Arthritis Index (AI) of each rat is the sum of the joint scores of the extremities. The criteria are as follows: red and swollen joints, 0 point; minor swollen joints, 1 point; swelling of the toe joints and plantar aspect, 2 points; paw swelling below the ankle joint, 3 points; all paws, including the ankle, were swollen for 4 points.
And (3) observation of pathological morphology of joint synovial tissue: taking the right posterior knee joint and synovial tissue about 2cm long, storing in 10% neutral formalin for fixation, decalcifying, dehydrating, transparentizing, soaking in wax, embedding, paraffin sectioning, and staining. And observing the hyperplasia and damage of joint synovium under a light microscope.
As a result: index scoring: compared with the normal group, the joint inflammation index of the model group is obviously increased (p <0.05), and compared with the model group, the joint inflammation index score of each administration group of the total sesquiterpene lactone extract is obviously reduced at the 28 th day of administration (p < 0.05).
Effect of total sesquiterpene lactone extract on collagen-induced arthritis model rat synovial histopathology: the results showed that normal synovial tissue was free of inflammatory cell infiltration and synovial cells were well-aligned. Synovial tissue of a rat in an arthritis model can be seen in synovial cell proliferation, lymphocytes are subjected to diffuse infiltration, and granuloma change can be seen. The synovium is slightly proliferated in the middle and high dose groups of the total sesquiterpene lactone extract and the positive control group, the inflammatory cell infiltration is less, and the inflammatory infiltration, proliferation and angiogenesis tissues are inhibited compared with the model group.
The influence of the total sesquiterpene lactone extract of saussurea involucrata on the content of IL-12 and IL-10 in serum of a collagen-induced arthritis model rat is as follows: compared with normal rats, the serum IL-12 level of the rats in the model group is obviously increased, and the IL-10 level is obviously reduced (p <0.05), which indicates that the model is established. Compared with the model group, the serum IL-12 level of each administration group of the total sesquiterpene lactone extract is remarkably reduced (p <0.01), and the IL-10 level is remarkably increased (p < 0.01).
And (4) conclusion: in conclusion, the total sesquiterpene lactone extract of saussurea involucrata can inhibit the progress of RA disease, relieve joint swelling, reduce inflammatory reaction and prevent bone destruction.
Experimental example 5 curative effect of total sesquiterpene lactone extract of saussurea involucrata on rheumatoid arthritis model rats
The method comprises the following steps: establishing a rat rheumatoid arthritis model, feeding 100mg/kg of aegilops tauschii total sesquiterpene lactone extract to a treatment group rat by intragastric administration every week, and continuously feeding for 6 weeks for 2 times every day. Detecting the pathological change degree of the rheumatoid arthritis by hematoxylin-eosin (HE) staining and toluidine blue staining; ELISA detection of TNF-alpha, IL-1 beta and IL-17 levels in tissues; and detecting the expression of the RANKL and the OPG protein by using Western blot.
As a result: the arthritis score and toe volume of the rats of the aegilops tauschii total sesquiterpene lactone extract administration group are obviously lower than those of the rats of the model group (p < 0.05). Compared with a model group, the RANKL protein content of the total sesquiterpene lactone extract administration group is obviously reduced, and the OPG protein content is obviously increased (p is less than 0.05); TNF-alpha, IL-1 beta and IL-17 levels were significantly reduced (p < 0.05).
And (4) conclusion: the total sesquiterpene lactone extract of saussurea involucrata can reduce the levels of ACCP and RF by inhibiting the expression of cytokines, and has the curative effect of treating the rheumatoid arthritis of rats.
Claims (10)
1. The total sesquiterpene lactone of saussurea involucrate is characterized by being obtained by the following steps:
pulverizing dried whole plant of saussurea involucrata, extracting with n-hexane or petroleum ether and ethyl acetate mixed solvent to obtain crude extract, and enriching by macroporous adsorbent resin or silica gel column chromatography to obtain total sesquiterpene lactone extract of saussurea involucrata.
2. The saussurea involucrate total sesquiterpene lactone of claim 1, characterized in that: the enrichment by macroporous adsorption resin means that the crude extract is added into a macroporous resin column D4020, D101 or AB-8, gradient elution is carried out by using an ethanol-water mixed solvent, liquid chromatography-mass spectrometry technology is adopted for analysis and detection, fractions containing sesquiterpene lactone are collected, and the fractions are combined and dried to obtain the total sesquiterpene lactone.
3. The saussurea involucrate total sesquiterpene lactone of claim 2, characterized in that: the gradient elution of the ethanol-water mixed solution is that 10-30% and 40-90% of ethanol in mass percentage concentration are sequentially adopted for gradient elution.
4. The saussurea involucrate total sesquiterpene lactone of claim 1, characterized in that: and the step of silica gel column chromatography refers to adding the crude extract to a silica gel column, performing gradient elution by using a mixed organic solvent, collecting fractions containing the sesquiterpene lactone, merging the fractions, and drying to obtain the total sesquiterpene lactone.
5. The saussurea involucrate total sesquiterpene lactone of claim 4, wherein: the mixed organic solvent is n-hexane: ethyl acetate is 20: 1-1: 20; n-hexane: dichloroethane is 30: 1-1: 30; petroleum ether-: ethyl acetate is 15: 1-1: 20; petroleum ether: dichloroethane is 30: 1-1: 30; n-hexane: acetone is 20:1 to 1: 20.
6. The saussurea involucrate total sesquiterpene lactone of claim 1, characterized in that: the total sesquiterpene lactone in the saussurea involucrate total sesquiterpene lactone accounts for not less than 50% by mass.
7. The method for preparing total sesquiterpene lactones of saussurea involucrate as claimed in claim 1, comprising the steps of:
pulverizing dried whole plant of saussurea involucrata, extracting with n-hexane or petroleum ether and ethyl acetate mixed solvent to obtain crude extract, and enriching by macroporous adsorbent resin or silica gel column chromatography to obtain total sesquiterpene lactone extract of saussurea involucrata.
8. The method for preparing total sesquiterpene lactones of saussurea involucrate according to claim 7, wherein the method comprises the following steps: the enrichment by macroporous adsorption resin means that the crude extract is added into a macroporous resin column D4020, D101 or AB-8, gradient elution is carried out by using an ethanol-water mixed solvent, liquid chromatography-mass spectrometry technology is adopted for analysis and detection, fractions containing sesquiterpene lactone are collected, and the fractions are combined and dried to obtain total sesquiterpene lactone; the gradient elution of the ethanol-water mixed solution is that 10-30% and 40-90% of ethanol in mass percentage concentration are sequentially adopted for gradient elution.
9. The method for preparing total sesquiterpene lactones of saussurea involucrate according to claim 7, wherein the method comprises the following steps: the silica gel column chromatography refers to adding the crude extract to a silica gel column, performing gradient elution by using a mixed organic solvent, collecting fractions containing sesquiterpene lactone, merging, and drying to obtain total sesquiterpene lactone, wherein the mixed organic solvent is n-hexane: ethyl acetate is 20: 1-1: 20; n-hexane: dichloroethane is 30: 1-1: 30; petroleum ether-: ethyl acetate is 15: 1-1: 20; petroleum ether: dichloroethane is 30: 1-1: 30; n-hexane: acetone is 20:1 to 1: 20.
10. The use of the total sesquiterpene lactone of saussurea involucrate as claimed in claim 1 in the preparation of an anti-osteoarthritis medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110629111.9A CN113350390A (en) | 2021-06-05 | 2021-06-05 | Total sesquiterpene lactone of saussurea involucrata, preparation method and pharmaceutical application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110629111.9A CN113350390A (en) | 2021-06-05 | 2021-06-05 | Total sesquiterpene lactone of saussurea involucrata, preparation method and pharmaceutical application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113350390A true CN113350390A (en) | 2021-09-07 |
Family
ID=77532546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110629111.9A Pending CN113350390A (en) | 2021-06-05 | 2021-06-05 | Total sesquiterpene lactone of saussurea involucrata, preparation method and pharmaceutical application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113350390A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116585300A (en) * | 2023-05-30 | 2023-08-15 | 苏州大学附属第一医院 | Application of cynarin in preparation of medicines for preventing or treating osteonecrosis of femoral head |
-
2021
- 2021-06-05 CN CN202110629111.9A patent/CN113350390A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116585300A (en) * | 2023-05-30 | 2023-08-15 | 苏州大学附属第一医院 | Application of cynarin in preparation of medicines for preventing or treating osteonecrosis of femoral head |
| CN116585300B (en) * | 2023-05-30 | 2024-04-19 | 苏州大学附属第一医院 | Application of cynarin in preparation of medicines for preventing or treating osteonecrosis of femoral head |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xing et al. | Chemical constituents, biological functions and pharmacological effects for comprehensive utilization of Eucommia ulmoides Oliver | |
| KR100864455B1 (en) | A Composition comprising the extract of complex herb improving Liver Cirrhosis, cytotoxicity and liver injury for preventing and treating of liver disease | |
| US8168238B2 (en) | Extracts of Aquilaria hulls and use thereof in the treatment of cancer | |
| WO2018058261A1 (en) | Traditional chinese medicine composition for treating psoriasis and preparation method thereof | |
| TWI300352B (en) | Water soluble extract from plant of solanum genus and the preparation process thereof, and pharmaceutical composition containing the water soluble extract | |
| WO2021249420A1 (en) | Use of kadsura heteroclita (roxb.) craib agent in preparation of medicament for resisting rheumatoid arthritis | |
| CN103479963A (en) | Traditional Chinese medicine capsules for treating rheumatoid arthritis and preparation method thereof | |
| WO2008145064A1 (en) | The method for a sequoyitol-containing extract obtaining from the genus of trifolium, sobyean and ginkgo biloba and use thereof | |
| Gong et al. | Traditional uses, phytochemistry, pharmacology, applications, and quality control of Gastrodia elata Blume: a comprehensive review | |
| CN113350390A (en) | Total sesquiterpene lactone of saussurea involucrata, preparation method and pharmaceutical application thereof | |
| CN104027428B (en) | Preparation method of traditional Chinese medicine compound and application of traditional Chinese medicine compound in prevention and treatment of senile dementia | |
| KR100733764B1 (en) | Composition comprising the cortex extract of albizzia julibrissin or kuraridinol isolated therefrom for preventing or treating hyperlipidemia | |
| KR100601390B1 (en) | Anti-Obesity ingredients from medicinal plants and their composition | |
| RU2519769C1 (en) | Agent possessing antineoplastic and immunomodulatory action | |
| CN112274586B (en) | Chinese herbal compound preparation for treating hepatic fibrosis and preparation method and application thereof | |
| CN113694104B (en) | Traditional Chinese medicine composition with protection effect on chemical liver injury and liver regeneration promotion function, preparation method and application thereof | |
| CN106822095A (en) | A kind of medicine and its application in pharmacy for preventing and treating fatty liver and obesity | |
| KR100529991B1 (en) | An extract of acanthopanax koreanum for the treatment or prevention of hepatitis or the liver protective drug | |
| KR100679291B1 (en) | A composition comprising an extract of ?????101 crude drug complex as an effective ingredient for preventing and treating atherosclerosis | |
| CN114736182B (en) | Compound for resisting myocardial ischemia reperfusion injury, dai medicine composition and application thereof | |
| CN113230294A (en) | Total coumarin in ' ' Welv ', its preparation and medicinal use | |
| CN103446220B (en) | Herba Artemisiae Annuae Radix Tripterygii Wilfordii medicine is to composition of medicine, preparation method and application | |
| CN106063802A (en) | Cacumen Myricariae Germanicae effective site, Its Preparation Method And Use | |
| US10329316B2 (en) | Phenylpropanoid compound and preparation method and use thereof | |
| CN112402566B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating gonarthromeningitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication |